HOUSTON, Texas, June 16, 2026
Nexalin Technology announced that two clinical abstracts evaluating its proprietary Deep Intracranial Frequency Stimulation (DIFS™) platform have been accepted for presentation at the 2026 NYC Neuromodulation Conference, a leading scientific event focused on next-generation neurostimulation technologies. The accepted studies highlight preliminary clinical results from Nexalin’s proprietary 15 mA, 77.5 Hz non-invasive neurostimulation platform, demonstrating meaningful improvements across anxiety, depression, insomnia, and quality of life. The presentations provide additional scientific visibility for the company’s innovative brain stimulation technology as Nexalin advances global clinical, regulatory, and commercialization initiatives.
Phase 1 Results Support Advancement into Phase 2 Studies
The accepted abstracts are based on findings from an eight-week prospective clinical trial conducted at the Institute of Psychiatry, Hospital das Clínicas, University of São Paulo. Participants diagnosed with generalized anxiety disorder and comorbid insomnia received 20 treatment sessions over four weeks, followed by a four-week observation period. Results showed a 77.8% anxiety response rate at the end of treatment, with anxiety symptoms improving rapidly during the study. Researchers reported a reduction of 14.73 points on the Hamilton Anxiety Rating Scale (HAM-A) by the fifth treatment session and a total reduction of 18.30 points by Session 20, with benefits maintained during the follow-up period. In addition, depressive symptoms improved substantially, with Hamilton Depression Rating Scale (HAMD) scores decreasing by 9.90 points, while both response and remission rates reached 66.7% at the completion of treatment.
Sustained Sleep and Quality-of-Life Benefits Support Platform Potential
Beyond anxiety and depression, the study demonstrated significant improvements in sleep quality and overall well-being. Patients experienced meaningful reductions in insomnia severity as measured by the Pittsburgh Sleep Quality Index (PSQI), with improvements remaining statistically significant throughout the eight-week follow-up period. Investigators also reported measurable enhancements in overall quality of life, alongside positive trends across additional patient-reported outcome measures. Importantly, the therapy maintained a favorable safety profile, with no serious adverse events, seizures, or manic/hypomanic episodes reported during the study. These findings suggest that Nexalin’s DIFS™ technology may offer a non-invasive and drug-free therapeutic option capable of addressing multiple interconnected neuropsychiatric conditions simultaneously.
Advertisement
Scientific Recognition Strengthens Global Commercial and Regulatory Strategy
The acceptance of two abstracts at a major neuromodulation conference further strengthens the scientific foundation supporting Nexalin’s proprietary neurotechnology platform. Unlike conventional neurostimulation approaches, the company’s DIFS™ system utilizes high-power frequency-based stimulation designed to reach deeper brain structures associated with mood regulation, sleep, and other neurological functions. Nexalin believes this differentiated mechanism may provide a competitive advantage as it advances its FDA De Novo regulatory pathway, expands clinical development programs, and prepares for broader commercialization efforts. The company also views the positive study results as strategically important for international markets, particularly Brazil, where the clinical trial was conducted and where preparations are underway for a potential product launch. With increasing scientific recognition and growing clinical evidence, Nexalin continues to position its DIFS™ platform as a next-generation solution in the rapidly evolving field of neurostimulation and mental health technology.
Source: Nexalin Technology press release
